<DOC>
	<DOCNO>NCT00570063</DOCNO>
	<brief_summary>To assess efficacy safety investigational compound PF-02545920 treatment schizophrenia . PF-02545920 effective placebo reduce symptom associate schizophrenia .</brief_summary>
	<brief_title>Double Blind , Randomized , 3 Week Inpatient Study To Evaluate The Safety &amp; Efficacy Of PF-02545920 Compared With Placebo</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Have current diagnosis schizophrenia . 2 . Increase symptoms past 24 week . 3 . Willing remain inpatient duration trial . 1 . Evidence history clinically significant medical problem . 2 . Females childbearing potential . 3 . A primary psychiatric diagnosis schizophrenia . 4 . A diagnosis substance abuse dependence last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Schizophrenia , acute exacerbation , PF-02545920</keyword>
</DOC>